NICE u-turn backs Sanofi’s Gaucher disease drug
The National Institute of Health and Care Excellence (NICE) has issued a positive Final Evaluation Determination (FED) recommending Cerdelga (eliglustat) as a first-line treatment for adults with the condition within its marketing authorisation, superseding a previous provisional rejection.